by birdflu666

July 18, 2009

from VoxRoxx Website

 

Baxter scientists patented the “swine flu” vaccine two years before outbreak of “novel swine flu” virus. Austrian Baxter scientist involved in H1N1 vaccine patent also advises World Health Organization!

 

Otfried Kistner, the head of virology at Baxter’s Austrian subsidiary in Orth an der Donau, which contaminated 72 kilos of vaccine material with the live bird flu virus and sent it to 16 labs this February, was part of the Austrian-based Baxter team that applied for a provisional patent for the “swine flu” H1N1 vaccine in August 2007, almost two years before the first “swine flu” outbreak in Mexico City in April2009 in a location about 50 kilometers from a Baxter facility.

Baxter’s Vaccine Patent Application US 2009/0060950 A1 gives “Kistner et al” as the applicant for the patent for the H1N1 vaccine that was provisionally filed on August 28, 2007.

Also Kistner is an advisor to WHO and took part in the WHO meeting in Geneva 2005 on the Evaluation and Development of Influenza Pandemic Vaccines.

It was WHO which supplied Baxter with the live bird flu virus that Baxter used to contaminate 72 kilos of vaccine material, sending it to 16 labs in four countries, nearly sparking a pandemic in February.

 

 

 


 

 

 

 

Big Pharma

Baxter Files Swine Flu Vaccine Patent a Year Ahead of Outbreak
by Lori Price
July 18, 2009
legitgov.org

from GlobalResearch Website

Barack Opharma issues the ultimate bad news during his weekly Friday night bad news dump: Legal immunity set for swine flu vaccine makers 17 Jul 2009.

 

The last time the government embarked on a major vaccine campaign against a new swine flu, thousands filed claims contending they suffered side effects [paralysis, death] from the shots. This time, the government has already taken steps to head that off.

 

Vaccine makers and federal officials will be immune from lawsuits that result from any new swine flu vaccine, under a document signed by Secretary of Health and Human Services Kathleen Sebelius, government health officials said Friday.

 

The document signed by Sebelius last month grants immunity to those making a swine flu vaccine, under the provisions of a 2006 law for public health emergencies.

 

Baxter Files Swine Flu Vaccine Patent a Year Ahead of Outbreak

US20090060950A1 to Baxter International filed 28th August 2008

by Lara

10 Jul 2009

 

Baxter Vaccine Patent Application US 2009/0060950 A1:

'In particular preferred embodiments the composition or vaccine comprises more than one antigen... such as influenza A and influenza B in particular selected from of one or more,

  • of the human H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7 subtypes

  • of the pig flu H1N1, H1N2, H3N1 and H3N2 subtypes

  • of the dog or horse flu H7N7, H3N8 subtypes

  • of the avian H5N1, H7N2, H1N7, H7N3, H13N6, H5N9, H11N6, H3N8, H9N2, H5N2, H4N8, H10N7, H2N2, H8N4, H14N5, H6N5, H12N5 subtypes'

 

Baxter can take no more H1N1 flu vaccine orders

16 Jul 2009

 

While at least 50 governments have placed orders or are negotiating with drug companies for supplies of flu vaccine against the [their] fast spreading H1N1 strain, the lone U.S.-based maker has already taken on as much as it can handle.

 

Baxter International Inc said on Thursday it has taken orders from five countries, including Britain, Ireland and New Zealand, for a total of 80 million doses of H1N1 vaccine and will not take any more.

'Clearly we believe this demand has the potential to translate into a significant opportunity.'

 

Baxter 2Q Profit Up 7.9%; Full-Year Guidance Raised

16 Jul 2009

 

Baxter International Inc. posted a stronger-than-expected 7.9% rise in second-quarter profit with help from improved margins and product sales that continued to avoid any hits from the economic downturn.

 

The medical-products maker boosted its 2009 earnings guidance while saying the increase doesn't reflect at this point any contribution from making a vaccine for the H1N1 flu strain.

 

Baxter reported a second-quarter profit of $587 million, or 96 cents a share, up from $544 million, or 85 cents a share, a year earlier.

 

Baxter working on vaccine to stop swine flu, though admitted sending live pandemic flu viruses to subcontractor

by Lori Price

26 Apr 2009

 

The OMFG moment of the century: Illinois-based Baxter working on vaccine to 'stop' swine flu outbreak in Mexico 25 Apr 2009 Specialty drug maker Baxter International Inc. will work with the World Health Organization to develop a vaccine that could stem [foment] an outbreak of a deadly swine flu strain in Mexico.

 

Baxter spokesman Christopher Bona said Saturday that the Deerfield, Ill.-based company has asked the WHO for a sample of the flu strain.

 

He says Baxter has patented technology that allows the company to develop vaccines in half the time it usually takes - about 13 weeks instead of 26.

 

Baxter admits sending live avian flu viruses to subcontractor

Baxter admits contaminated seasonal flu product contained live bird flu virus 27 Feb 2009 The company that released contaminated flu virus material from a plant in Austria confirmed Friday that the experimental product contained live H5N1 avian flu viruses.

 

And an official of the World Health Organization's European operation said the body is closely monitoring the investigation into the events that took place at Baxter International's research facility in Orth-Donau, Austria.

 

Human trial of swine flu vaccine 'soon'

15 Jul 2009

 

The federal government has defended its policy of not following the United Kingdom's lead and rushing out a swine flu vaccine. Biopharmaceutical company CSL will start clinical vaccine trials on 240 healthy adults in Adelaide next week.

 

The vaccine is due to be rolled out in October.